DMPQ二盐酸盐 | 1123491-15-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: DMPQ二盐酸盐
• 英文名称: DMPQ Dihydrochloride
• 英文别名: 5,7-dimethoxy-3-pyridin-4-ylquinoline;dihydrochloride
• CAS: 1123491-15-5
• 化学式: C16H16Cl2N2O2
• 分子量: 339.2
• InChiKey: YBBAOKYVJCNJIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.16
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  44.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Method of treating cancers with SAHA and pemetrexed
  申请人：Pluda James

  公开号：US20070117815A1

  公开（公告）日：2007-05-24

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

  本发明涉及一种治疗需要的受试者癌症的方法，通过向需要的受试者施用一定量的组蛋白去乙酰化酶（HDAC）抑制剂或其药用可接受的盐或水合物的第一量，以及一定量的抗癌药物。HDAC抑制剂和抗癌药物可以被施用以包含治疗有效量。在各种方面，HDAC抑制剂和抗癌药物的效果可能是相加的或协同的。
• Biomarker combinations for colorectal cancer
  申请人：Diagnoplex

  公开号：EP2544006A1

  公开（公告）日：2013-01-09

  The present invention relates to methods and kits for the detection of predetermined biomarker BIRC4BP for early diagnosis and management of colorectal cancer.

  本发明涉及用于早期诊断和管理结直肠癌的预定生物标志物 BIRC4BP 的检测方法和试剂盒。
• Methods for diagnosis, prognosis and methods of treatment
  申请人：Nodality, Inc.

  公开号：EP2860247A1

  公开（公告）日：2015-04-15

  This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells.

  本发明涉及诊断、预后和确定治疗方法的方法和组合物。样本（如临床样本）中存在的细胞的生理状态可用于诊断或预后病情（如慢性淋巴细胞白血病）、选择患者进行治疗、监测治疗以及修改或优化治疗方案。细胞的生理状态可通过比较一个细胞（如癌细胞）与另一个细胞（如正常细胞）的一个或多个激活元件的胞内状态（如信号分子的磷酸化状态）来确定。在相关细胞中加入一种或多种调节剂（如抑制剂或激活剂），可进一步对细胞的生理状态进行分类。在某些实施方案中，本发明涉及确定细胞群表型特征的方法。
• Producing mesodermal cell types and methods of using the same
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10787640B2

  公开（公告）日：2020-09-29

  Methods are provided for the generation of mesodermal cell types and derivatives thereof. Also provided are methods for generating purified populations of mesodermal cell types and derivatives thereof. The instant disclosure also provides methods of screening for cellular responses of the generated mesodermal cell types and derivatives thereof. Also provide are methods for screening for organismal phenotypes induced by introduction of the generated mesodermal cell types and derivatives thereof. Treatment methods making use of the generated mesodermal cell types and derivatives thereof are also provided. The instant disclosure also provides systems, compositions, and kits for practicing the methods of the disclosure.

  提供了生成中胚层细胞类型及其衍生物的方法。还提供了生成纯化的中胚层细胞类型及其衍生物的方法。本发明还提供了筛选所产生的中胚层细胞类型及其衍生物的细胞反应的方法。本发明还提供了通过引入所产生的中胚层细胞类型及其衍生物来筛选生物表型的方法。还提供了利用生成的中胚层细胞类型及其衍生物的治疗方法。本发明还提供了用于实施本发明方法的系统、组合物和试剂盒。
• METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER
  申请人：Merck and Co., Inc.

  公开号：EP1942907A2

  公开（公告）日：2008-07-16